Descripción
Summary of the evidence supporting Saccharomyces boulardii CNCM I-745 as a unique yeast probiotic with distinct advantages over bacterial probiotics in specific clinical scenarios. Intrinsic antibiotic resistance allows concurrent use with antimicrobial therapy.
Figure 6
DiagramSource Paper
Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review.Cite This Figure
![Figure 6: Summary of the evidence supporting Saccharomyces boulardii CNCM I-745 as a unique yeast probiotic with distinct advantages over bacterial probiotics in specific clinical scenarios. Intrinsic antibiotic resistance allows concurrent use with antimicrobial therapy.]() > Source: Sarath Gopalan et al. "Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narra." *Cureus*, 2023. PMID: [37927652](https://pubmed.ncbi.nlm.nih.gov/37927652/)
<figure> <img src="" alt="Summary of the evidence supporting Saccharomyces boulardii CNCM I-745 as a unique yeast probiotic with distinct advantages over bacterial probiotics in specific clinical scenarios. Intrinsic antibiotic resistance allows concurrent use with antimicrobial therapy." /> <figcaption>Figure 6. Summary of the evidence supporting Saccharomyces boulardii CNCM I-745 as a unique yeast probiotic with distinct advantages over bacterial probiotics in specific clinical scenarios. Intrinsic antibiotic resistance allows concurrent use with antimicrobial therapy.<br> Source: Sarath Gopalan et al. "Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narra." <em>Cureus</em>, 2023. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37927652/">37927652</a></figcaption> </figure>